Lithium, widely recognized for its use in batteries and psychiatric treatments, is attracting attention for its potential role in protecting against dementia, according to emerging research. Naturally occurring in trace amounts in water, soil, and some foods such as cabbage and potatoes, lithium has long been used in high doses to manage depression and bipolar disorder. Now, studies are exploring whether much lower doses might benefit brain health and reduce the risk of Alzheimer’s disease.
Lithium is not classified as an essential nutrient, and there is no official recommended daily intake, though some scientists suggest a provisional 1 mg daily dose for adults. At therapeutic levels, lithium carbonate helps stabilize mood by regulating neurotransmitters such as dopamine and enhancing calming receptors in the brain. More recently, neuroscientists have identified additional mechanisms through which lithium may support cognitive function.
Dr. Ivan Koychev, an NHS consultant neuropsychiatrist and clinical associate professor at Imperial College London, explained that lithium appears to help maintain the brain’s ability to form and preserve synaptic connections—critical for memory and learning. Lithium also inhibits glycogen synthase kinase-3 (GSK-3), an enzyme linked to the formation of toxic tau protein tangles, a hallmark of Alzheimer’s disease.
Research indicates that abnormal accumulation of tau protein and beta-amyloid plaques in the brain interferes with memory and cognitive processes. One leading hypothesis suggests that elevated GSK-3 activity contributes to this pathology, possibly worsened by age-related declines in the brain’s toxin clearance mechanisms.
A decade-long Harvard Medical School study published last year reported lower lithium levels in brain tissue from individuals with mild cognitive impairment compared to healthy counterparts. Notably, lithium was concentrated within amyloid plaques, implying these deposits might deplete available lithium needed for neuronal protection. In animal models, lithium supplementation improved memory and reduced Alzheimer’s-like brain changes, whereas lithium deficiency accelerated disease progression.
Additional ecological studies have associated naturally higher lithium levels in regional drinking water with reduced dementia rates. However, a small U.S. clinical trial testing low-dose lithium in older adults with mild cognitive impairment did not replicate the robust memory benefits observed in animal studies.
Experts caution that larger, well-funded clinical trials are necessary to establish lithium’s efficacy and safety in dementia prevention. Challenges include the long preclinical phase of Alzheimer’s, which often precedes symptoms by 10 to 20 years, and the low commercial incentive to develop lithium-based treatments due to its low cost and lack of patent protection.
Dosage and formulation remain areas of investigation. Psychiatric treatments involve high doses—ranging from 400 mg to 1.2 grams of lithium carbonate daily—which carry risks such as kidney impairment, thyroid dysfunction, and cardiac effects. The Harvard research utilized lithium orotate, which may be less prone to sequestration in amyloid plaques, but its pharmacological profile in humans is not fully understood. Current clinical trials, including one at Johns Hopkins University testing lithium orotate and a UK study examining low-dose lithium carbonate for individuals at risk of Alzheimer’s, aim to clarify these issues.
While some clinicians suggest that individuals with a family history of dementia might consider short-term low-dose lithium supplementation under medical supervision, others emphasize caution. Dr. Koychev notes that more evidence is needed before routine lithium use can be recommended, particularly for those with existing kidney or thyroid conditions. Health professionals stress that any supplement use should be discussed with a primary care provider.
As research continues, lithium’s role in neuroprotection remains a promising but not yet proven avenue for dementia prevention.